These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34579244)

  • 1. Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque.
    Naderi Sohi A; Kiani J; Arefian E; Khosrojerdi A; Fekrirad Z; Ghaemi S; Zim MK; Jalili A; Bostanshirin N; Soleimani M
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines.
    Morais P; Adachi H; Yu YT
    Front Cell Dev Biol; 2021; 9():789427. PubMed ID: 34805188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases.
    Vadovics M; Muramatsu H; Sárközy A; Pardi N
    Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
    Takanashi A; Pouton CW; Al-Wassiti H
    Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA.
    Lin WS; Bostic WKV; Malmstadt N
    Lab Chip; 2024 Jan; 24(2):162-170. PubMed ID: 38165143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
    Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
    Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2.
    Mao S; Li S; Zhang Y; Long L; Peng J; Cao Y; Mao JZ; Qi X; Xin Q; San G; Ding J; Jiang J; Bai X; Wang Q; Xu P; Xia H; Lu L; Xie L; Kong D; Zhu S; Xu W
    Nano Today; 2023 Feb; 48():101730. PubMed ID: 36570700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines.
    Bae KH; Shunmuganathan B; Zhang L; Lim A; Gupta R; Wang Y; Chua BL; Wang Y; Gu Y; Qian X; Tan ISL; Purushotorman K; MacAry PA; White KP; Yang YY
    NPJ Vaccines; 2024 Feb; 9(1):43. PubMed ID: 38396073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
    Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
    Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins.
    Bykonia EN; Kleymenov DA; Gushchin VA; Siniavin AE; Mazunina EP; Kozlova SR; Zolotar AN; Usachev EV; Kuznetsova NA; Shidlovskaya EV; Pochtovyi AA; Kustova DD; Ivanov IA; Dmitriev SE; Ivanov RA; Logunov DY; Gintsburg AL
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
    Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing.
    El-Mayta R; Padilla MS; Billingsley MM; Han X; Mitchell MJ
    J Vis Exp; 2023 Jan; (191):. PubMed ID: 36744791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.
    Marcos-Villar L; Perdiguero B; Anthiya S; Borrajo ML; Lou G; Franceschini L; Esteban I; Sánchez-Cordón PJ; Zamora C; Sorzano CÓS; Jordá L; Codó L; Gelpí JL; Sisteré-Oró M; Meyerhans A; Thielemans K; Martínez-Jiménez F; López-Bigas N; García F; Alonso MJ; Plana M; Esteban M; Gómez CE
    NPJ Vaccines; 2024 Mar; 9(1):53. PubMed ID: 38448450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory.
    Ndeupen S; Qin Z; Jacobsen S; Estanbouli H; Bouteau A; Igyártó BZ
    bioRxiv; 2021 Jul; ():. PubMed ID: 33688649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
    McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
    Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability.
    Zhang L; More KR; Ojha A; Jackson CB; Quinlan BD; Li H; He W; Farzan M; Pardi N; Choe H
    NPJ Vaccines; 2023 Oct; 8(1):156. PubMed ID: 37821446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles.
    Omata D; Kawahara E; Munakata L; Tanaka H; Akita H; Yoshioka Y; Suzuki R
    Mol Pharm; 2024 Nov; 21(11):5672-5680. PubMed ID: 39324825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques.
    Garrido C; Curtis AD; Dennis M; Pathak SH; Gao H; Montefiori D; Tomai M; Fox CB; Kozlowski PA; Scobey T; Munt JE; Mallroy ML; Saha PT; Hudgens MG; Lindesmith LC; Baric RS; Abiona OM; Graham B; Corbett KS; Edwards D; Carfi A; Fouda G; Van Rompay KKA; De Paris K; Permar SR
    bioRxiv; 2021 Apr; ():. PubMed ID: 33851156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Thermostable mRNA Vaccine against COVID-19.
    Zhang NN; Li XF; Deng YQ; Zhao H; Huang YJ; Yang G; Huang WJ; Gao P; Zhou C; Zhang RR; Guo Y; Sun SH; Fan H; Zu SL; Chen Q; He Q; Cao TS; Huang XY; Qiu HY; Nie JH; Jiang Y; Yan HY; Ye Q; Zhong X; Xue XL; Zha ZY; Zhou D; Yang X; Wang YC; Ying B; Qin CF
    Cell; 2020 Sep; 182(5):1271-1283.e16. PubMed ID: 32795413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.